Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced that CEO Geoff Green will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022. The virtual presentation is scheduled from 2:00 to 2:30 p.m. ET and will be accessible via Longeveron's website. The company specializes in cellular therapies targeting chronic, aging-related, and life-threatening conditions, focusing on its lead product, LOMECEL-B™. Longeveron is currently conducting Phase 1 and 2 trials for various conditions, including Alzheimer’s disease and Aging Frailty.

MIAMI, March 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer at Longeveron, will present at the upcoming Oppenheimer 32^nd Annual Healthcare Conference on Wednesday, March 16, 2022. Details of Longeveron’s participation follow below:

• Format: Virtual Company Presentation
  Date: Wednesday, March 16, 2022
  Time: 2:00 - 2:30 p.m. ET

The presentation can be accessed at https://bit.ly/3q41EUb or by visiting the investor relations section of the Company’s website (www.longeveron.com). Following the presentation, an archived replay will be available on Longeveron’s website.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.

Contact:
Brendan Payne
Stern Investor Relations
Tel: (212) 362-1200
Email: Brendan.payne@sternir.com

Source: Longeveron

FAQ

What is Longeveron Inc. presenting at the Oppenheimer Healthcare Conference?

Longeveron Inc. will present its developments in cellular therapies, focusing on its lead investigational product LOMECEL-B™, at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022.

When is the Longeveron presentation scheduled?

The Longeveron presentation is scheduled for March 16, 2022, from 2:00 to 2:30 p.m. ET.

How can I access the Longeveron presentation?

The presentation can be accessed virtually via the link provided in the press release or through Longeveron's investor relations page on their website.

What are the main clinical trials Longeveron is sponsoring?

Longeveron is currently sponsoring Phase 1 and 2 clinical trials for conditions including Aging Frailty, Alzheimer’s disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome, and hypoplastic left heart syndrome.

What is the focus of Longeveron's cellular therapies?

Longeveron focuses on developing cellular therapies for chronic, aging-related, and life-threatening conditions, using medicinal signaling cells derived from young, healthy adult donors.